The Middle EAST Biologics Contract Manufacturing Market was valued at USD 1.5 billion in 2024 and is projected to reach USD 3.8 billion by 2034, registering a CAGR of 9.5%. This growth trajectory is underpinned by several key factors, including increasing demand for biologics, advancements in biomanufacturing technologies, and a growing emphasis on outsourcing among pharmaceutical companies....